Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.45 |
| ▸ | GSR | P00390 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596693 | 0.81 | POLB (0.59) | CYP1A2NOTUMBRD9GSRPOLB | |
| SCHEMBL597092 | 0.78 | NOTUM (0.48) | CYP1A2NOTUMBRD9GSRPOLB | |
| SCHEMBL27830345 | 0.78 | CYP1A2 (0.49) | CYP1A2NOTUMBRD9GSRPOLB | |
| SCHEMBL594708 | 0.78 | KMT2A (0.50) | CYP1A2NOTUMPOLBELANEGAA | |
| SCHEMBL27830347 | 0.78 | AGBL2 (0.51) | CYP1A2NOTUMBRD9GSRPOLB | |
| SCHEMBL597107 | 0.78 | NOTUM (0.48) | CYP1A2NOTUMPOLBELANENPY5R | |
| SCHEMBL4286769 | 0.74 | CYP1A2 (0.52) | CYP1A2NOTUMBRD9GSRPOLB | |
| SCHEMBL17819335 | 0.74 | CYP1A2 (0.49) | CYP1A2NOTUMBRD9GSRGAA | |
| SCHEMBL6315486 | 0.73 | NOTUM (0.59) | CYP1A2NOTUMBRD9GSRPOLB | |
| SCHEMBL596533 | 0.73 | CYP1A2 (0.54) | CYP1A2NOTUMBRD9GSRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466284-B2 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRA ZENECA AB (SE) | 2013-06-18 | — | — | US | disclosed |
| US-8466284-B2 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRA ZENECA AB (SE) | 2013-06-18 | — | — | US | disclosed |
| US-8466284-B2 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRA ZENECA AB (SE) | 2013-06-18 | — | — | US | disclosed |
| US-8410114-B2 | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial | ASTRAZENECA AB (SE) | 2013-04-02 | — | — | US | disclosed |
| US-20120108610-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-8114881-B2 | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial | ASTRAZENECA AB (SE) | 2012-02-14 | — | — | US | disclosed |
| WO-2011110852-A1 | POLYMORPHIC FORMS OF 6- [2- (4 -CYANOPHENYL) - 2H - PYRAZOL - 3 - YL] - 5 -METHYL - 3 - OXO - 4 - (TRIFLUOROMETHYL - PHENYL) 3,4-DIHYDROPYRAZINE-2-CARBOXYLIC ACID ETHYLAMIDE | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224229-A1 | Novel Crystalline Form | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224229-A1 | Novel Crystalline Form | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224229-A1 | Novel Crystalline Form | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20100280048-A1 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRAZENECA R&D (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280048-A1 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRAZENECA R&D (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280048-A1 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ASTRAZENECA R&D (SE) | 2010-11-04 | — | — | US | disclosed |
| EP-2217591-A1 | SOME 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090209555-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| WO-2009061271-A1 | SOME 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061271-A1 | SOME 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009058076-A1 | 2-PYRAZINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | WO | disclosed |
| EP-2018377-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | Astra Zeneca AB (SE) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007129963-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224229-A1 | Novel Crystalline Form | UACA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC1 | CYP1A2 230/4885NOTUM 2722/4885BRD9 4229/4885 |
| US-20100280048-A1 | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase | ELANE, SERPINB1, MPO | CYP1A2 615/4885NOTUM 1764/4885BRD9 1652/4885 |
| US-20090209555-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | SERPINB1, ELANE, EPX | CYP1A2 279/4885NOTUM 3125/4885BRD9 4302/4885 |
| US-20120108610-A1 | 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | SERPINB1, ELANE, EPX | CYP1A2 279/4885NOTUM 3125/4885BRD9 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.